SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
– ONM-501 is a dual-activating polyvalent STING agonist for immuno-oncology applications formulated with OMNI™, the…
SOUTHLAKE, Texas – April 12, 2022 – OncoNano Medicine, Inc. today announced positive results from…
March 10, 2022 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced two poster presentations at the…
– Former Assistant Secretary of Health and Admiral in the U.S. Public Health Service to…
-Will convert previous grant awards to an equity investment in OncoNano’s Series B -Additional capital…
Update on pH-sensitive fluorescent nanoprobe from late-breaking oral presentation at The World Molecular Imaging Congress…
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology…
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor…
OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of…